Physician profile
Nathaniel Schaefer
NPI 1992080048
$8,303.72
in general payments reported to CMS, 2019-2025
24 companies · $3,880 in 2025
The $3,880 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.36 · 2022: $555 · 2023: $2,354 · 2024: $1,494 · 2025: $3,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,323 · Consulting Fee: $1,125 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,323.42 |
| Consulting Fee | $1,125.00 |
| Education | $279.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,394.17 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $1,461.07 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $812.21 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $551.06 | 2022-2025 | |
| Almirall LLC | $350.95 | 2022-2023 | Seysara, Klisyri |
| Ucb, INC. | $286.98 | 2023-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $282.84 | 2023-2025 | Dupixent, Libtayo |
| Pfizer INC. | $277.66 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $273.01 | 2024-2025 | |
| Galderma Laboratories, L.P. | $268.97 | 2024-2025 | Nemluvio, Aklief |
| Incyte Corporation | $211.86 | 2023 | Opzelura |
| Arcutis Biotherapeutics, INC. | $168.13 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $141.83 | 2023-2024 | Vtama |
| Amgen INC. | $140.63 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $135.33 | 2023-2024 | Sotyktu |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $133.52 | 2025 | Ebglyss, Taltz |
| Organon LLC | $109.82 | 2025 | Vtama |
| Biofrontera INC. | $98.15 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $86.30 | 2023 | Arazlo, Jublia, Siliq |
| Stryker Corporation | $32.80 | 2022 | |
| Heron Therapeutics, INC. | $30.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.32 | 2024 | Cyltezo |
| Organogenesis INC. | $20.36 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.75 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.